No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
Objective. About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many of which are potentially curable.
Record created on 2011-12-16, modified on 2016-08-09